bit.bio

New ioCells Product Hub | Find the right cells - fast! 🔗 Discover the latest addition to our website. Link in the comments. A one-stop destination to quickly find the opti-ox powered human iPSC-derived cells you need for your experiments. With intuitive filters by cell type, disease area, or genome modification, our hub makes it simple to pinpoint the tools that match your research goals. From Alzheimer’s and ALS to CRISPR-Ready ioCells, everything is organised for scientists - so you can focus on advancing your work. Simplify your search. Discover ioCells. #cells #optiox #ioCells #launch #humancells #research #science #DrugDevelopment #DrugDiscovery

As 2024 wraps up, we asked our scientists a simple question: What were your research highlights of the year? Turns out, scientists love a good paper (who knew, right?). They came up with a list so long it nearly needed its own journal. But don’t worry, we’ve done the hard work and narrowed it down for you. Here are 9 selected research highlights of 2024: 📄 Johnston K.G. et al. Nat. Methods 21, 1597–1602 (2024) 💡Illustrates how small, focused datasets can be incredibly powerful when integrated with large public data atlases. 🔗 https://hubs.ly/Q02_z9zL0 📄 Zhang S. et al. Blood Adv. epub ahead of print (2024) 💡Introduces a new immunomodulator for immune evasion, offering fresh perspectives on designing immune therapies. 🔗 https://hubs.ly/Q02_z9yQ0 📄Lorenzo-Martín L.F. et al. Nat. Biotechnol. epub ahead of print (2024). 📄Mitrofanova O. et al. Cell Stem Cell 31, 1175–1186.e7 (2024). 💡Demonstrate how biomimetic hydrogels shaped as microchannels create organoids that faithfully replicate in vivo colon function. 🔗 https://hubs.ly/Q02_z9Vp0 🔗 https://hubs.ly/Q02_zb8b0 📄Tycko J. et al. Nat. Biotechnol. epub ahead of print (2024). 📄Wilson C.M. et al. bioRxiv Oct 28:2024.10.28.620517 (2024). 📄Hyungseok C.M. et al. bioRxiv 2024.10.28.620683 (2024) 💡Utilising large-scale combinatorial transcription effector discovery screens, using domains from transcription factors and epigenetic regulators. 🔗 https://hubs.ly/Q02_z96K0 🔗 https://hubs.ly/Q02_zb960 🔗 https://hubs.ly/Q02_z99s0 📄Rood J.E. et al. Cell 187, 4520–4545 (2024) 💡Lays out a bold vision for linking genes to cellular and tissue outcomes. 🔗 https://hubs.ly/Q02_z9CB0 📄 Zhang H. et al. Cell epub ahead of print (2024) 💡A multiscale human iPSC-based platform, comprising cardiac fibroblasts, cardiomyocytes and endothelial cells in a high-throughput screen, identifying MD2 as a target for cardiac fibrosis. 🔗 https://hubs.ly/Q02_z9Xh0 Which paper caught your attention in 2024? Share it in the comments below! Kevin Johnston, UCLA; G. Grant Welstead, Clade Therapeutics; Luis Francisco Lorenzo Martín, EPFL; Olga Mitrofanova, Matthias Lutolf, Luke Gilbert, Caroline Wilson, University of California, San Francisco; Arc Institute; Josh Tycko, Harvard Medical School, Stanford University; Genentech; Hao Zhang, Joseph C. Wu, Stanford University; Springer Nature, Cell Press, bioRxiv & medRxiv #ResearchHighlights, #iPSCCells, #SyntheticBiology, #CellBiology, #DrugDiscovery, #LifeScience, #optiox, #ioCells

🎉Celebrating Nobel Day🎉 Congratulations to today’s Nobel Prize winners! On this day, we honour the groundbreaking achievements that have shaped science and medicine. Advancements like these fuel our collective mission to push the boundaries of what’s possible in healthcare and deliver life-changing treatments to patients worldwide. At bit.bio, we are proud that Nobel Prize-winning science underpins our understanding of cell identity, our cutting-edge cell coding platform, and our innovative development of human cell products for drug discovery and therapeutics. Let’s celebrate the spirit of discovery and the scientists whose work inspires us all. #bitbio #NobelDay #ScienceForHealth #SyntheticBiology #Synbio #iPSC #CRISPR #Stemcells #Biotech #CellProgramming #PrecisionMedicine

Interested in learning about the complexities of in vitro liver modelling for predicting human toxicity and pharmacology? Then watch our recent webinar: https://hubs.ly/Q02_44Nv0 Join Dr. Stephen Ferguson of National Institute of Environmental Health Sciences (NIEHS) and Thomas Brown of bit.bio as they explore the principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro. This session examines advancements in cell systems replicating human liver responses to environmental toxins, such as PFAS, and the principles and challenges shaping the field. Also, bit.bio's Thomas Brown presents on the use of opti-ox™ deterministic cell programming to develop hiPSC-derived hepatocytes as a potential alternative to primary hepatocytes and immortalised cell lines. Highlights include: ✅Advances in replicating liver functionality ✅Toxicological impact of complex xenobiotics ✅Consistent, scalable approaches to functional hepatocyte modelling with iPSC-derived cells #LiverResearch #Toxicology #InVitroModelling #Pharmacology #iPSCs #LiverToxicity #DrugDiscovery #optiox #ioCells

How do mutations in PSEN1 and APP impact secretion of amyloid-β peptides? Using our human opti-ox™ deterministically programmed iPSC-derived glutamatergic neurons with Alzheimer’s disease-relevant mutations in PSEN1 and APP, we have shown significant changes in the secretion of amyloid-β peptides compared to the genetically matched control over a 30 day period. This toolkit offers scientists highly characterised and physiologically relevant iPSC-derived cell models to study Alzheimer’s disease. Check out the data! PSEN1 M146L data: https://hubs.ly/Q02-TWZR0 APP KM670/671NL (Swedish) data: https://hubs.ly/Q02-TYnp0 APP V717I (London) data: https://hubs.ly/Q02-T_X00 #DrugDiscovery #AlzheimersDisease #optiox #ioCells #neurodegeneration

We recently collaborated with Technology Networks to bring you a Teach Me in 10 episode featuring our very own scientists Dr Mitzy Rios de Anda and Georgina Miller. Watch here: https://lnkd.in/eZ7sKVNj In the video, you can learn about astrocytes, the most abundant glial cells in the CNS, which play critical roles in maintaining neuronal support, the blood-brain barrier, secretion of cytokines, and bidirectional communication with microglia. Dysfunction in astrocytes is implicated in neurodegenerative diseases, making them a key focus for research and drug discovery. #research #DrugDiscovery #optiox #ioCells #astrocytes #NeurodegenerativeDisease #iPSCs #CNS

Screen candidate ASOs in a human-relevant, easy-to-use neuronal model. ASOs with gapmer chemistry were introduced into ioGlutamatergic Neurons by gymnosis. RT-qPCR shows ~90% knockdown of the target gene by the positive control ASO and strong separation of the assay signal for the positive and negative controls. ⬇️Click the link in the comments to see all data. Investigate efficacy, potency and toxicity of ASO candidates using opti-ox deterministically cell programmed iPSC-derived glutamatergic neurons. This rapidly maturing, robust and highly characterised system overcomes the challenges of cell culture heterogeneity and donor variability associated with immortalised cell lines and primary cell sources. Switch to a consistent, defined and scalable disease model and accelerate your translational research and drug discovery workflows. Data courtesy of Charles River Laboratories. #DrugDiscovery #ASOs #optiox #ioCells #neurodegeneration

DATA ALERT! Phenotypes of mitochondrial dysfunction and reduced neuronal network activity demonstrated in our human iPSC-derived Huntington’s disease model. ⬇️ Click the link in the comments to see how these cells can support your disease modelling! When paired with the genetically matched control, these opti-ox deterministically cell programmed glutamatergic neurons provide a rapidly maturing, robust platform to investigate the impact of a 50 CAG repeat expansion in the huntingtin gene, and are easy to integrate into translational research and drug discovery applications. #DrugDiscovery #HuntigtonsDisease #optiox #ioCells #neurodegeneration

NEW ioCELLS QUAD-CULTURE DATA! Studying the complexities of the human brain requires models that reflect its cellular diversity. In vitro multi-cellular models aim to provide a simple tool for studying the interactions between neurons and glial cells, enabling scientists to de-risk their neuroscience translational research. Our collaborators at Charles River Laboratories developed a quad-culture model including ioOligodendrocyte-like cells, ioGlutamatergic Neurons, ioMicroglia, and human iPSC-derived astrocytes. This in vitro model can be used for neurotoxicity and neuroinflammation assays, offering a powerful tool to study neuron-glial cell interactions in a dish. By replicating key cellular interactions in vitro, the model supports early-stage drug discovery and has the potential to improve translational relevance for diseases like Alzheimer’s and multiple sclerosis. ⬇️ Click the link in the comments to learn more about ioCells #Neuroscience #BrainModeling #CellCulture #Neurodegeneration #Neuroinflammation #AlzheimersDisease #MultipleSclerosis #optiox #ioCells

WEBINAR ALERT - JUST 1 DAY LEFT! Join Dr. Stephen Ferguson of National Institute of Environmental Health Sciences (NIEHS) and Thomas Brown of bit.bio as they explore the principles, pitfalls, and progress in modelling human liver toxicity and pharmacology in vitro. 🔗 Register now: https://hubs.ly/Q02ZSc590 This session will examine advancements in cell systems replicating human liver responses to environmental toxins, such as PFAS, and the principles and challenges shaping the field. Also, bit.bio's Tom Brown will present the use of opti-ox™ deterministic cell programming to develop hiPSC-derived hepatocytes as a potential alternative to primary hepatocytes and immortalised cell lines. Highlights include: ✅Advances in replicating liver functionality ✅Toxicological impact of complex xenobiotics ✅Consistent, scalable approaches to functional hepatocyte modelling with iPSC-derived cells #LiverResearch #Toxicology #InVitroModelling #Pharmacology #iPSCs #LiverToxicity #DrugDiscovery #optiox #ioCells